Literature DB >> 3949973

Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia.

B Teng, A D Sniderman, A K Soutar, G R Thompson.   

Abstract

The turnover of apolipoprotein B (apo B) in very low density, intermediate density, and low density lipoproteins (VLDL, IDL, and LDL) and in the light and heavy fractions of LDL was determined in seven patients with hyperapobetalipoproteinemia (hyperapo B), six normolipidemic subjects, and five patients with heterozygous familial hypercholesterolemia (FH). After receiving an injection of 125I-VLDL, hyperapo B patients were found to have a higher rate of synthesis of VLDL-apo B than controls (40.1 vs. 21.5 mg/kg per d, P less than 0.05) but a reduced fractional catabolic rate (FCR) (0.230 vs. 0.366/h, P less than 0.01). After receiving an injection of 131I-LDL, hyperapo B patients had higher rates of LDL-apo B synthesis than controls (23.1 vs. 13.0 mg/kg per d, P less than 0.001), as did FH patients (22.7 mg/kg per d). The FCR of LDL was similar in hyperapo B patients and controls (0.386 vs. 0.366/d) but was markedly decreased in FH patients (0.192/d). Most subjects exhibited precursor-product relationships between VLDL and IDL, and all did between IDL and light LDL; an analogous relationship between light and heavy LDL was evident in most hyperapo B patients and controls but not in FH patients. Simultaneous injection of differentially labeled LDL fractions and deconvolution analysis showed increased light LDL synthesis with normal conversion into heavy LDL in hyperapo B, whereas in FH conversion of light LDL was reduced and there was independent synthesis of heavy LDL. These data show that the increased concentration of LDL-apo B in hyperapo B is solely due to increased LDL synthesis, which is secondary to increased VLDL synthesis; in contrast, in FH there is both an increase in synthesis of LDL (which is partly VLDL-independent) and reduced catabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3949973      PMCID: PMC423449          DOI: 10.1172/JCI112360

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  The design and analysis of isotope experiments.

Authors:  D B ZILVERSMIT
Journal:  Am J Med       Date:  1960-11       Impact factor: 4.965

2.  Determination of B protein of low density lipoprotein directly in plasma.

Authors:  A Sniderman; B Teng; M Jerry
Journal:  J Lipid Res       Date:  1975-11       Impact factor: 5.922

3.  Catabolism of very low density lipoprotein B apoprotein in man.

Authors:  M F Reardon; N H Fidge; P J Nestel
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

4.  A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

Authors:  G R Warnick; J J Albers
Journal:  J Lipid Res       Date:  1978-01       Impact factor: 5.922

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Heterogeneity of plasma low density lipoproteins manifestations of the physiologic phenomenon in man.

Authors:  W R Fisher
Journal:  Metabolism       Date:  1983-03       Impact factor: 8.694

7.  The independent synthesis of intermediate density lipoproteins in type III hyperlipoproteinemia.

Authors:  M F Reardon; M E Poapst; G Steiner
Journal:  Metabolism       Date:  1982-05       Impact factor: 8.694

8.  The characterization of a discrete series of low density lipoproteins in the disease, hyper-pre-beta-lipoproteinemia. Implications relating to the structure of plasma lipoproteins.

Authors:  M G Hammond; W R Fisher
Journal:  J Biol Chem       Date:  1971-09-10       Impact factor: 5.157

9.  Quantitative studies of very low density lipoprotein: conversion to low density lipoprotein in normal controls and primary hyperlipidaemic states and the role of direct secretion of low density lipoprotein in heterozygous familial hypercholesterolaemia.

Authors:  E D Janus; A Nicoll; R Wootton; P R Turner; P J Magill; B Lewis
Journal:  Eur J Clin Invest       Date:  1980-04       Impact factor: 4.686

10.  The metabolism of apolipoprotein B in subjects with hypertriglyceridemia and polydisperse LDL.

Authors:  W R Fisher; L A Zech; P Bardalaye; G Warmke; M Berman
Journal:  J Lipid Res       Date:  1980-08       Impact factor: 5.922

View more
  26 in total

1.  Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families.

Authors:  J de Graaf; D W Swinkels; A F de Haan; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

2.  Familial combined hyperlipoproteinemia.

Authors:  J Genest
Journal:  CMAJ       Date:  1991-09-15       Impact factor: 8.262

3.  Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach.

Authors:  L Berglund; J L Witztum; N F Galeano; A S Khouw; H N Ginsberg; R Ramakrishnan
Journal:  J Lipid Res       Date:  1998-04       Impact factor: 5.922

4.  Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein.

Authors:  K M Cianflone; M H Maslowska; A D Sniderman
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

Review 5.  Apolipoproteins and metabolism in atherosclerosis.

Authors:  A M Gotto
Journal:  Trans Am Clin Climatol Assoc       Date:  1990

Review 6.  Genetic influences on susceptibility to atherosclerosis in the young.

Authors:  P O Kwiterovich
Journal:  Bull N Y Acad Med       Date:  1989-12

7.  Acylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with another serum basic protein, BP II.

Authors:  P Kwiterovich; M Motevalli; M Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

8.  Lipoprotein lipase activity in patients with combined hyperlipidaemia.

Authors:  M Seed; F Mailly; D Vallance; E Doherty; A Winder; P Talmud; S E Humphries
Journal:  Clin Investig       Date:  1994-01

9.  Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome.

Authors:  Sung Woo Kwon; Se-Jung Yoon; Tae Soo Kang; Hyuck Moon Kwon; Jeong-Ho Kim; Jihyuk Rhee; Sung-Ju Lee; Jong-Kwan Park; Jae Yun Lim; Young Won Yoon; Bum Kee Hong
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

10.  Regulation of plasma LDL: the apoB paradigm.

Authors:  Allan D Sniderman; Jacqueline De Graaf; Patrick Couture; Ken Williams; Robert S Kiss; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.